A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

Detalles Bibliográficos
Autores principales: Wang, Weidong, Lv, Wang, Wang, Hui, Xu, Yang, Yan, Junrong, Shen, Han-Ming, Shan, Liqun, Hu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404941/
https://www.ncbi.nlm.nih.gov/pubmed/37554188
http://dx.doi.org/10.1016/j.gendis.2023.02.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404941/
https://www.ncbi.nlm.nih.gov/pubmed/37554188
http://dx.doi.org/10.1016/j.gendis.2023.02.019

Ejemplares similares